Search clinical trials for: Lu AF82422

Total 290 results

Bivision Pharmaceuticals, Inc.

Recruiting

Phase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer

Prostate Cancer

China
Nanjing First Hospital, Nanjing Medical University

Unknown

177Lu-PSMA-I＆T PSMA Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer

China
Jonsson Comprehensive Cancer Center
POINT Biopharma

Active, not recruiting

177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR Study (LUNAR)

Prostate Adenocarcinoma | Stage IVB Prostate Cancer AJCC v8 | Oligometastatic Prostate Carcinoma | Recurrent Prostate Adenocarcinoma

United States
Xinlu Wang
Sinotau Pharmaceutical Group

Recruiting

A Clinical Study of [177Lu]Lu-XT117 Injection in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
Lantheus Medical Imaging
POINT Biopharma

Available

Expanded Access Treatment With [Lu-177]-PNT2002 for Adult Patients With Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Castration-Resistant Prostatic Cancer

United States
Southern California University of Health Sciences
Sun Ten Pharmaceutical Co Ltd.

Completed

Effects of Lagenbone on Bone Mineral Density

Osteoporosis

United States
H. Lundbeck A/S

Terminated

A Study to Evaluate the Long-term Safety and Tolerability of Lu AF20513 and the Antibody Response in Patients With Alzheimer's Disease (AD)

Alzheimer's Disease

Finland, Sweden
H. Lundbeck A/S

Completed

Pharmacokinetic Properties of Idalopirdine (Lu AE58054) in Subjects With and Without Impaired Kidney Function

Alzheimer Disease

Germany
Ralph NULL Salloum
Children's Hospital Medical Center, Cincinnati

Recruiting

Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors

High Grade Glioma | Medulloblastoma | Meningioma | Anaplastic Ependymoma | Recurrent Malignant Glioma | Recurrent Medulloblastoma | Refractory Malignant Glioma | Refractory Medulloblastoma | Recurrent Diffuse Intrinsic Pontine Glioma | Recurrent Primary Central Nervous System Neoplasm | Refractory Primary... and other conditions

United States
InQpharm Group

Completed

Benefit and Tolerability of IQP-LU-104 in Weight Loss

Obesity | Overweight

Germany
H. Lundbeck A/S

Recruiting

A Study Investigating the Movement of Lu AF28996 Into, Through, and Out of the Body of Healthy Men

Healthy Participants

United Kingdom
Debiopharm International SA

Recruiting

A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors

Pancreatic Ductal Adenocarcinoma (PDAC) | Colorectal Cancer (CRC) | Clear Cell Renal Cell Cancer (ccRCC)

France, Australia
H. Lundbeck A/S

Terminated

Study With Lu AF20513 in Patients With Mild Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI) Due to AD

Alzheimer Disease

Finland, Sweden
Peter MacCallum Cancer Centre, Australia
Endocyte; Movember Foundation; Medical Research Future Fund; E.J. Whitten Foundation...

Active, not recruiting

Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy (LuTectomy)

Prostatic Neoplasms

Australia
Medical University of Vienna

Recruiting

PSMA-RLT in Biochemically Recurrent PCa

Prostate Cancer Recurrent

Austria
Cellbion Co., Ltd.

Recruiting

A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy

Prostate Cancer | mCRPC

Korea, Republic of
H. Lundbeck A/S

Completed

Pharmacokinetics Properties of Single Oral Dosing of Lu AE58054 in Subjects With Hepatic Impairment (Mild and Moderate) and in Healthy Subjects

Heptic Impairment

Germany
Lawson Health Research Institute

Active, not recruiting

An Open Label Registry Study of Lutetium-177 (DOTA0, TYR3) Octreotate (Lu-DOTA-TATE) Treatment in Patients With Somatostatin Receptor Positive Tumours

Neuroendocrine Carcinoma

Canada
Advanced Accelerator Applications

Active, not recruiting

Post-Authorization Long-Term Safety Study of LUTATHERA (SALUS)

Neuroendocrine Tumors

United Kingdom, Portugal, Spain, France, United States
H. Lundbeck A/S

Recruiting

A Study Investigating Lu AG06474 in Healthy Young Participants

Healthy Participants

United States
Istituto Scientifico Romagnolo per lo Studio e...

Recruiting

Radiometabolic Therapy With 177Lu PSMA in PSMA PET/CT Positive Advanced/Metastatic Tumours: (LUBASKET)

Cancer

Italy
H. Lundbeck A/S

Completed

Lu AE58054 Added to Donepezil for the Treatment for Moderate Alzheimer's Disease

Alzheimer's Disease

Spain, Germany, Australia, Canada, Czech Republic, Italy, Poland
Providence Health & Services
Exelixis; Advanced Accelerator Applications SA

Active, not recruiting

Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors

Neuroendocrine Tumors

United States
Ruimin Wang
Sinotau Pharmaceutical Group

Recruiting

A Clinical Study of [177Lu]Lu-XT117 Injection in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
H. Lundbeck A/S

Completed

Study Investigating the Pharmacokinetic Properties of the Drug Lu AF35700 in Subjects With Liver Impairment and in Healthy Subjects

Hepatic Impairment

Germany
University of Iowa
Novartis

Not yet recruiting

177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry (LUMOD-ID)

Neuroendocrine Tumors | Neuroendocrine Tumor Grade 2 | Neuroendocrine Tumor Grade 1

United States
University College, London

Not yet recruiting

Trial of Lu-177 DOTATATE (Lutathera®) in Unlicensed Indications

Medullary Thyroid Carcinoma | Bronchial and Thymic Neuroendocrine Tumour | Paraganglioma/ Phaeochromocytoma | Those Requiring Repeat Peptide Receptor Radionuclide Therapy
Marnix Lam

Completed

Intra-arterial Lutetium-177-dotatate for Treatment of Patients With Neuro-endocrine Tumor Liver Metastases (LUTIA)

Neuroendocrine Tumors | Liver Metastases

Netherlands
H. Lundbeck A/S
Otsuka Pharmaceutical Co., Ltd.

Completed

Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil (STARBEAM)

Alzheimer's Disease

United States, Argentina, Brazil, Canada, Croatia, Czechia, Estonia, Finland, France, Hungary, Israel, Italy, Korea, Republic of, Lithuania, Poland, Portugal, Taiwan, United Kingdom, Ireland
POINT Biopharma, a wholly owned subsidiary of Eli...

Active, not recruiting

Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment (SPLASH)

Metastatic Castration-Resistant Prostate Cancer

United States, Canada, Netherlands, Sweden, France, United Kingdom
H. Lundbeck A/S

Terminated

A Study to Evaluate Lu AF90103 in Healthy Men

Healthy

Netherlands
AHS Cancer Control Alberta
Cross Cancer Institute

Active, not recruiting

Review of Medical Records of Patients Who Have Been Treated With Lutetium at the Cross Cancer Institute Between January 2010 and April 30, 2014

Neuroendocrine Tumors, NET

Canada
H. Lundbeck A/S
Otsuka Pharmaceutical Co., Ltd.

Completed

Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With an Acetylcholinesterase Inhibitor (STARBRIGHT)

Alzheimer's Disease

United States, Australia, Brazil, Czechia, Germany, Israel, Korea, Republic of, Mexico, Serbia, Singapore, Slovakia, Spain, Switzerland, Turkey, United Kingdom
H. Lundbeck A/S

Completed

Safety Study of Carbamylated Erythropoietin to Treat Patients With the Neurodegenerative Disorder Friedreich's Ataxia

Friedreich's Ataxia

Germany, Austria, Italy
Tine Gregersen, MD

Recruiting

Dosimetry Based PRRT Versus Standard Dose PRRT With Lu-177-DOTATOC in NEN Patients (DOBATOC)

Neuroendocrine Neoplasm

Denmark
H. Lundbeck A/S

Recruiting

Eptinezumab as Preventive Treatment of Migraine in Adults With Migraine (Sunrise)

Migraine

Poland, China, Spain, Georgia, Japan, Korea, Republic of, Taiwan, Slovakia
H. Lundbeck A/S

Completed

Eptinezumab in Adults With Migraine and Medication Overuse Headache (Sunlight)

Migraine | Medication Overuse Headache

Spain, China, Korea, Republic of, Taiwan, Georgia
David Bushnell
National Cancer Institute (NCI); National Institutes of Health (NIH); Progenics...

Withdrawn

A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors (SPORE-3)

Neuroendocrine Tumors | Gastro-enteropancreatic Neuroendocrine Tumor

United States
National Cancer Centre, Singapore
Novartis; Advanced Accelerator Applications

Recruiting

Phase II 177Lu-DOTATATE Study in Metastatic NPC With a Safety Run-in (SG-AAA-II-01)

Metastatic Nasopharyngeal Cancer

Singapore
H. Lundbeck A/S

Completed

Study With Lu AF87908 in Healthy Participants and Participants With Alzheimer's Disease

Healthy | Alzheimer Disease

United States
H. Lundbeck A/S

Completed

Safety and Tolerability of Lu AG06474 in Healthy Young Men

Healthy

United States
H. Lundbeck A/S

Completed

A Single Dose Study of Lu AG09222 in a Headache Model With Healthy Subjects

Healthy

Denmark
H. Lundbeck A/S

Completed

Single Ascending Dose Study of Lu AF76432 in Healthy Young Men

Healthy

United Kingdom
H. Lundbeck A/S

Completed

Safety and Tolerability Study of Lu AF35700 After Repeated Dosing in Patients With Schizophrenia

Schizophrenia

United States
University of California, Davis
National Institutes of Health (NIH)

Recruiting

Molecularly Targeted Theranostic Approach for the Detection and Treatment of Metastatic Carcinomas

Metastatic Cancer

United States
Novartis Pharmaceuticals

Recruiting

A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.

Glioblastoma

Spain, Switzerland, France, Portugal, United States
Radboud University Medical Center

Completed

Phase II Study of Lutetium-177 Labeled Girentuximab in Patients With Advanced Renal Cancer

Metastatic Clear Cell Renal Cell Carcinoma

Netherlands
Novartis Pharmaceuticals

Recruiting

Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma

Newly Diagnosed and Recurrent Glioblastoma

Spain, Israel, Portugal
H. Lundbeck A/S

Completed

Efficacy Study Exploring the Effect of Lu AE58054 as Augmentation Therapy in Patients With Schizophrenia

Schizophrenia | Cognition

Hong Kong, Thailand, Belgium, France, Germany, Italy, Poland, Taiwan
National Cancer Institute (NCI)

Recruiting

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

Stage IV Prostate Cancer AJCC v8 | Metastatic Prostate Small Cell Neuroendocrine Carcinoma | Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation | Metastatic Prostate Neuroendocrine Carcinoma

United States

Search clinical trials for: Lu AF82422

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Turkmenistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations